RxDoctor Payments DataLook up a doctor →

Gary Pang, MD

Pain Medicine · Riverside, CANPI 1851486310

Payments from drug & device makers

$439,158in general payments, 2019–2025

Across 411 payments — averaging $1068.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$270K
  • Anika Therapeutics, Inc.$150K
  • Nevro Corp.$4K
  • Medtronic$3K
  • Spinal Simplicity, LLC$2K
  • Abbott$2K
  • plus $8K from 30 others

What the payments were for

  • Travel & lodging$3,98821%
  • Food & beverage$14,92179%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$439,158 in reported general payments places this provider in the 95th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$199,337
Medicare patients
265
Services billed
3,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl14$13,967
BotoxOnabotulinumtoxina12$13,918
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen407$7,615
Lidocaine64$5,820
Pregabalin206$5,296
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen166$4,775
Buprenorphine24$4,641
Gabapentin414$4,183
Diclofenac Sodium69$2,748
Baclofen152$2,010
Fentanyl17$1,991
Naloxone Hcl29$1,710
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$1,548
Morphine Sulfate ErMorphine Sulfate54$1,387
Duloxetine Hcl78$950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$197$13,91812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 pain medicine providers in California.

Other pain medicine in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →